"Bergsland, Niels" . . "8" . "6"^^ . "Zhang, Ming" . "Environmental Factors Associated with Disease Progression after the First Demyelinating Event: Results from the Multi-Center SET Study" . "73028" . . "Tamano-Blanco, Miriam" . "Yu, Haoying" . "10.1371/journal.pone.0053996" . . . . . "Qu, Jun" . . . "Environmental Factors Associated with Disease Progression after the First Demyelinating Event: Results from the Multi-Center SET Study" . . "Environmental Factors Associated with Disease Progression after the First Demyelinating Event: Results from the Multi-Center SET Study"@en . . "RIV/00064165:_____/13:10189797!RIV14-MZ0-00064165" . "Hor\u00E1kov\u00E1, Dana" . "Badgett, Darlene" . "Zivadinov, Robert" . "[B16363A41293]" . "1932-6203" . . "Hussein, Sara" . . "Environmental Factors Associated with Disease Progression after the First Demyelinating Event: Results from the Multi-Center SET Study"@en . "http://dx.doi.org/10.1371/journal.pone.0053996" . "Kalincik, Tomas" . . "21"^^ . . "1" . "age; diagnosis; infection; antibodies; cytomegalovirus; smoking; risk-factors; brain atrophy; multiple-sclerosis; epstein-barr-virus"@en . "Kr\u00E1sensk\u00FD, Jan" . "000313429800079" . . "Duan, Xiaotao" . "Seidl, Zden\u011Bk" . "Weinstock-Guttman, Bianca" . "T\u00FDblov\u00E1, Michaela" . "Willis, Laura" . . . . . "Lelkov\u00E1, Petra" . "Objectives: To investigate the associations of environmental MS risk factors with clinical and MRI measures of progression in high-risk clinically isolated syndromes (CIS) after the first demyelinating event. Methods: We analyzed 211 CIS patients (age: 28.9 +/- 7.8 years) enrolled in the SET study, a multi-center study of high-risk CIS patients. Pre-treatment samples were analyzed for IgG antibodies against cytomegalovirus (anti-CMV), Epstein Barr virus (EBV) early nuclear antigen-1 (EBNA-1), viral capsid antigen (VCA), early antigen-diffuse (EA-D), 25 hydroxy-vitamin D3 and cotinine levels and HLA DRB1*1501 status. The inclusion criteria required evaluation within 4 months of the initial demyelinating event, 2 or more brain MRI lesions and the presence of two or more oligoclonal bands in cerebrospinal fluid. All patients were treated with interferon-beta. Clinical and MRI assessments were obtained at baseline, 6, 12, and 24 months. Results: The time to first relapse decreased and the number of relapses increased with anti-CMV IgG positivity. Smoking was associated with increased number and volume of contrast-enhancing lesions (CEL) during the 2-year period. The cumulative number of CEL and T2 lesions during the 2-year period was greater for individuals in the highest quartile of anti-EBV VCA IgG antibodies. The percent loss of brain volume was increased for those in the highest quartile of with anti-EBV VCA IgG antibodies. Conclusions: Relapses in CIS patients were associated with CMV positivity whereas anti-EBV VCA positivity was associated with progression on MRI measures, including accumulation of CEL and T2 lesions and development of brain atrophy."@en . "US - Spojen\u00E9 st\u00E1ty americk\u00E9" . . "Dwyer, Michael G." . . . . "Van\u011B\u010Dkov\u00E1, Manuela" . "Ramanathan, Murali" . "RIV/00064165:_____/13:10189797" . "PLoS ONE" . . . . "Objectives: To investigate the associations of environmental MS risk factors with clinical and MRI measures of progression in high-risk clinically isolated syndromes (CIS) after the first demyelinating event. Methods: We analyzed 211 CIS patients (age: 28.9 +/- 7.8 years) enrolled in the SET study, a multi-center study of high-risk CIS patients. Pre-treatment samples were analyzed for IgG antibodies against cytomegalovirus (anti-CMV), Epstein Barr virus (EBV) early nuclear antigen-1 (EBNA-1), viral capsid antigen (VCA), early antigen-diffuse (EA-D), 25 hydroxy-vitamin D3 and cotinine levels and HLA DRB1*1501 status. The inclusion criteria required evaluation within 4 months of the initial demyelinating event, 2 or more brain MRI lesions and the presence of two or more oligoclonal bands in cerebrospinal fluid. All patients were treated with interferon-beta. Clinical and MRI assessments were obtained at baseline, 6, 12, and 24 months. Results: The time to first relapse decreased and the number of relapses increased with anti-CMV IgG positivity. Smoking was associated with increased number and volume of contrast-enhancing lesions (CEL) during the 2-year period. The cumulative number of CEL and T2 lesions during the 2-year period was greater for individuals in the highest quartile of anti-EBV VCA IgG antibodies. The percent loss of brain volume was increased for those in the highest quartile of with anti-EBV VCA IgG antibodies. Conclusions: Relapses in CIS patients were associated with CMV positivity whereas anti-EBV VCA positivity was associated with progression on MRI measures, including accumulation of CEL and T2 lesions and development of brain atrophy." . . . "P(NT13237), Z(MSM0021620849)" . "Havrdov\u00E1, Eva" . "8"^^ . . .